Share Name Share Symbol Market Type Share ISIN Share Description
Xenetic Bio LSE:XEN London Ordinary Share GB00B08NWV55 ORD 0.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 6.00p 0.00p 0.00p - - - 0.00 05:00:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.2 -3.4 -0.9 - 24.48

Xenetic Bio (XEN) Latest News

Real-Time news about Xenetic Bio (London Stock Exchange): 0 recent articles
More Xenetic Bio News
Xenetic Bio Takeover Rumours

Xenetic Bio (XEN) Share Charts

1 Year Xenetic Bio Chart

1 Year Xenetic Bio Chart

1 Month Xenetic Bio Chart

1 Month Xenetic Bio Chart

Intraday Xenetic Bio Chart

Intraday Xenetic Bio Chart

Xenetic Bio (XEN) Discussions and Chat

Xenetic Bio (XEN) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Xenetic Bio trades in real-time

Xenetic Bio (XEN) Top Chat Posts

DateSubject
02/9/2015
14:23
corrientes: Wow ! who would have thought that the announcement of opening of digital corporate communication channels would give such a boost to the share price today, since there's already a blog. Seems the price is being slowly and quietly (up till now anyway) manoeuvred to an acceptable Nasdaq opening price level, despite what have really been pathetic volumes up until now. Really don't understand this, but just maybe XBIO is going to really shine fairly shortly, and I don't expect anyone here will be complaining, save for maybe not being able to buy more shares.
13/4/2015
21:31
ashthorpedo: All will become clear very soon. Annual results are due by 15th so we will find out how the fundraising is coming along. In total agreement with you Trotters, Maguire is responsible for this fiasco. If he wasn't aware he should have been aware that european investors would have had a problem dealing on OTC. He has put the blame for the fall in share price on a few investors selling the odd thousand shares knocking the price of the company down by millons but the reality is that there is no buyers in america otherwise the price would not have fallen. He talks endlessly about derisking biotech with testing drugs in Russia and India but we have not seen any results for a long time and by the sound of the last conference call never will. I can't see investors paying much more than the current price unless the money comes from Baxter again or Rusnano. I can see a placing at 25c and Maguire will be saying that he has done a great job getting a 20% premium to the current price. I hope I'm wrong.
08/1/2015
13:12
digger18: It would seem that 3,244,784 shares were issued for intellectual property, so yes a dilution. However, the rest currently unexercised warrants based on a Min share price of $0.77 and also performance criteria. So IMHO would not have thought this would be the main cause of the share price fall. I see the main issue being an expected placing in order to raise capital required by end of Feb 2015. Ie uncertainty of the likelihood,source and extent of the capital raising.
19/12/2014
12:04
ashthorpedo: Scott has been banging on about how excited he is about Oncohist for the past 2 years and we were promised data from the trials in Russia for the past year. If the results from these trials that Scott is privy to are so exciting the falling share price would be solved in an instant and liquidity would increase. Why has the release of the results of these trials been delayed?
19/12/2014
10:56
ashthorpedo: I got this from Investopedia Listing requirements for NASDAQ Listing Requirements for All Companies Each company must have a minimum of 1,250,000 publicly-traded shares upon listing, excluding those held by officers, directors or any beneficial owners of more then 10% of the company. In addition, the regular bid price at time of listing must be $4, and there must be at least three market makers for the stock. However, a company may qualify under a closing price alternative of $3 or $2 if the company meets varying reequirements. Each listing firm is also required to follow Nasdaq corporate governance rules 4350, 4351 and 4360. Companies must also have at least 450 round lot (100 shares) shareholders, 2,200 total shareholders, or 550 total shareholders with 1.1 million average trading volume over the past 12 months. Over the past year Xenetic has never had a daily trading volume of 1.1 million shares so if that is the criteria for a NASDAQ listing then it will not happen until 2016 at the earliest. Or perhaps it is because we don't have 2,200 total shareholders. A share placing will achieve this but at what price? At the current price to raise any meaningful amount of capital, shareholders will be massively diluted. Also raising capital at these prices will also delay any NASDAQ listing as it will take longer to achieve the minimum entry level share price.
18/11/2014
16:53
ashthorpedo: I would have thought that this would have been the reason "The Company estimates that as of the date of the filing of this Form 10-Q, the Company has working capital available to fundits current business plan to the middle of the first quarter of 2015. Since its inception, the Company has incurred, and continues to incur, significant losses from operations. The Company has historically relied upon the proceeds of public and non-public financing activities to support the working capital requirements necessary to pursue the on-going research, development and commercialization of its intellectual property and know-how. During September 2014, the Company entered into a non-exclusive financial advisory and placement agent agreement with an investment bank firm. Through introductions made by that firm and through other sources, the Company has met with and presented its business plan to potential investors for the purpose of raising working capital through a private placement transaction. Based upon the progress of on-going discussions, the Company has a reasonable expectation that it will raise sufficient working capital to meet its obligations over the next twelve months, and therefore has prepared the financial statements on the going concern basis. The Company’s planned capital raise is expected to be through debt (convertible or otherwise), by means of an equity-based instrument, or a combination thereof. The amount of capital the Company will be able to raise in that timeframe will determine to what extent the Company will be able to continue to fund its core programs and related operating costs, and/or accelerate programs as they relate to its preferred level of discretionary spend on pre-clinical developments and clinical trials delivered by external service providers. While these financial statements have been prepared on a going concern basis, if the Company does not raise additional working capital by the end of 2014, there is no assurance that the Company would be able to continue its operations as now currently planned beyond the middle of the first quarter of 2015 and could raise substantial doubt over the Company’s ability to continue as a going concern. Under such circumstances the Company would first expect to reduce the scale of its pre-clinical programs from the current planned levels, which would likely compel it to reduce general and administrative expenses, defer or cease research and development projects, and delay or cease the purchase of significant clinical research services until it is able to obtain sufficient financing." So the share price has dropped to 30c to sell which is 6p old money which starts to make the following statements seem terribly silly. Xenetic Biosciences is finally embarking on the process of "serious value" growth, according to its chief executive. Chief executive Scott Maguire recently colourfully compared this process as being like a "battleship leaving the dock". Maguire said the long term benefits of being a US-centric organisation will become apparent as US markets give "significantly" greater value to firms like Xenetic with its broad proprietary drug pipeline. "When I present at conferences in the US, they think our market cap is five to ten times higher than it actually is and they are quite shocked that it's US$35 million and not US$250/350 million," said Maguire. It would seem that the US doesn't place anymore value on the company that the UK market. In fact the only difference is that I can't sell a single share.
29/9/2014
20:17
trotterstrading: Not liking this otcqb market, silly little sales have hammered the share price 50% in 6 months! Who is selling at these levels the bid/offer spread is ridiculous! The board need to get the Nasdaq listing ASAP before the share price drops to single digits!
01/7/2014
13:43
corrientes: I have about 24,000 XBIO shares, which I recently wanted my broker,Pershing, to put into nominee name to expedite a smooth and speedy sale when the time is right ! This they refuse to do as the share price 'falls well below what they can take in' whatever that vague statement means. On further enquiry it transpires that they need .2 of a $ when they require .5 of a $, a statement which again doesn't make a lot of sense to me anyway,particularly given the present share price. Xenetic themselves when transferring to OTC, recommended a firm called Glendale Securities of Sherman Oaks CA for disposals, but comments about them have not exactly been flattering and I suspect they wouldn't be cheap to deal with. I know that spreads and costs would make this an expensive share to sell at any point, and anyway I intend to remain a holder. The broker is going to send the share certificate back to me. Has anyone here got any suggestions as to the best course of action ?
12/8/2013
13:53
buywell2: Re all these RNS's we have been getting Getting a Nasdaq listing would cost $ Millions .... but there is another way 16 July 2013 XENETIC BIOSCIENCES PLC Xenetic Biosciences seeks to effect its migration to the United States The board of Xenetic Biosciences plc ("Xenetic") notes the recent share price movement. It is able to confirm that it is currently seeking to identify a United States ("US") company ("US Counterparty") suitable to make an all share offer for the entire issued and to be issued share capital of Xenetic, to be effected by a UK Court sanctioned scheme of arrangement ("Scheme") under the Companies Act 2006 ("Possible Offer"). By this method, Xenetic hopes to achieve access to a quotation on a US stock market more easily, more quickly and in a more cost-effective manner than would be possible were it to apply for such a quotation itself. As previously announced by Xenetic, it has been implementing its longer term strategy as regards the migration of its corporate seat to, and its expansion in, the US, noting the significant value gap that exists between the biotechnology sector in the UK and in the US where the Company believes the sector is better understood and more widely followed. Any Possible Offer would be conditional on Xenetic agreeing terms with a suitable US Counterparty and all relevant US legal and regulatory requirements being satisfied to enable the migration to be completed in the manner intended. This is an announcement falling under Rule 2.4 of the Code. It does not represent a firm intention by any person to make an offer under Rule 2.7 of the Code. There can be no certainty that any offer will ultimately be made and as of the date of this announcement, Xenetic is not in discussions with any US Counterparty. Background The Board of Xenetic ("Xenetic Board") believes that at the present time smaller quoted bioscience companies, in general, have a higher profile and a better investor following in the US than is found in European markets in general and in the UK market, in particular. It believes that by achieving a quotation for Xenetic on a US stock market, significant benefits will accrue to Xenetic and its shareholders including, but not exclusively: · the ability to attract and incentivise qualified personnel with orphan drug development and launch experience; · easier access to finance; · a better rating of Xenetic's shares; and · higher levels of share trading liquidity. The Xenetic Board has considered a number of options to achieve its goal, including seeking a quotation of Xenetic's shares directly on a US stock market and seeking a merger with an existing US quoted biotechnology company with complementary activities. Following careful consideration of the issues the Xenetic Board determined that the best way is to be acquired by a SEC reporting, unlisted company, which can achieve a quotation on a major US stock market within a reasonable period, and to effect such an acquisition by a Scheme. Xenetic's plan is for it to be acquired on a share-for-share basis by a US Counterparty, where the level of effective dilution to Xenetic's shareholders is modest and agreed in advance. This means that, other than for an acceptable level of dilution (which is deemed to be the "cost" of achieving Xenetic's aims) and the fees and costs of the Possible Offer, the entity formed by the completion of the Possible Offer will be as near as possible the same entity as Xenetic, with the same assets and liabilities, save that it would have a new US holding company. Xenetic hopes to conclude the process of securing a Possible Offer during 2013. On the completion of any Possible Offer it is expected that Xenetic's shares will cease to be traded on AIM. It is Xenetic's intention to seek a quotation of the US Counterparty's shares on a US Exchange with minimal delay to minimise the period during which on-market trading will not be possible. Possible US Counterparties Any potential US Counterparty or person representing such a company interested in discussing a possible transaction with Xenetic along the lines set out herein should contact Adam Hart at adam.hart@londonbridgecapital.com.
20/9/2011
07:18
buywell2: From what I can remember from a previous older broker note the value attached to ErePoxen alone with SIL at the old rates agreed was 11p Thought so I wonder if after +ve progress re trials is announced ErePoxen and SuliXen take the share price back to 28p ? .... presumably the updated brokers note will value both higher with larger %'s going to Xenetic , so maybe over 40p as Histone technology was not around then ? Lipoxen (Pharmaceuticals & Biotechnology, Buy, Mkt Cap £33m, share price 28p) - ErepoXen awaiting clarification from Canada Yesterday afternoon UK drug delivery specialist Lipoxen announced that it will have to await further clarification from the Canadian regulatory authorities before Phase-I Canadian dosing of ErepoXen (its long-acting formulation of erythropoietin to treat anaemia in renal dialysis patients) can commence. Canadian trials of the compound are being managed 'on the ground' by Canadian contract research organisation AnaPharm, working in collaboration with the Serum Institute of India and Lipoxen. To date the compound has received regulatory 'ethical approval' from Health Canada' Institutional Review Board. However, it now awaits further approval from Health Canada's Chemistry Committee and its Clinical Committee. In an announcement earlier this week Lipoxen stated that it hoped to start the Phase-I trial in July 2008, although given that additional clarification is required by two additional committees, patient dosing now looks unlikely to commence until Q4 2008. Although this expected 3-5 month delay is clearly disappointing, we nevertheless believe that the prospects for the drug remain exciting. The trial will follow a successful Indian Phase-I trial of the drug, which investigated the impact of 0.5, 1.5, 2.0 and 2.5 ug/Kg doses of the drug in 64 volunteers. Data for the first two doses (0.5 and 1.5ug), at 56 days, indicated that the drug was well tolerated and, at 1.5ug, potentially efficacious. Amongst the patients receiving the higher dose, there was a significant increase in reticulocytes and a sustained (28-day) increase in haemoglobin levels. This would suggest that the drug could be administered on a monthly basis, versus the current standard dose of once-weekly. Based on these results we believe that the outcome of a follow-up Canadian Phase-I trial is highly likely to be successful. We expect a 200-400 patient Indian Phase-II trial to start by the end of 2008, and a similar Canadian trial to commence once Phase-I is complete. ErepoXen utilises Lipoxen's unique PolyXen technology. This is a potential replacement for PEG (polyethylene glycol) – one of the pharma industry's most popular ways of extending the half life of a biologic drug. Unfortunately, PEG is non-biodegradable (toxicity issues), and thus so good at 'wrapping around' a drug (in order to prevent the body breaking it down – thereby extending its half-life) that it masks the drug's activity. However, unlike PEG, Lipoxen's PolyXen is a naturally occurring polymer (polysialic acid) found in the body. Potentially, it is therefore non-toxic, biodegradable and (importantly, as it is non-immunogenic) it does not adversely affect a drug's efficacy. Landsbanki estimates that over 2007 the combined European and US EPO market generated sales of $11.0bn (-7.8%). Clearly this represents a significant market opportunity for an improved longer-acting and potentially safer new entrant. We reiterate our Buy recommendation and 42p price target for Lipoxen. We believe that the company has adopted a relatively low-risk business model, applying two novel drug-delivery technologies (PolyXen and VesicALL, a new approach to vaccine delivery) to a range of previously approved and marketed compounds, with a view to improving patient compliance and therapeutic efficacy significantly. As such, the company remains unexposed to inherently high-risk early stage drug development. In addition, Lipoxen is applying a third novel formulation therapy (ImuXen), via an experienced partner, to relatively low-risk vaccine development. We value Lipoxen at 42p per share, based on an aggressively discounted (50% premium to cost of capital), risk-adjusted sum-of-the-parts analysis of SuliXen (29p), ErepoXen (11p), additional PolyXen compounds (2p) and forecast FY2008 net cash (0.1p). As the VesicALL and ImuXen pipelines emerge into the clinic, they will significantly increase our fair value. Our valuation represents approximately 50% potential upside to the current share price of 28p, and underpins our Buy recommendation. Shawn Manning 020 7426 9522 Landsbanki
Xenetic Bio share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V: D:20161203 15:38:29